xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

301

ICAR SINONASAL TUMORS

TABLE XXV.9 (Continued)

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusions

Yanget al. 1707

1. ORR was 28.2%, DCR was 54.5%, TTR was 8.3 weeks 2. Median PFS was 17.4 months 3. 33% of patients had grade ≥ 3AEs

1. ORR 2. DCR 3. TTR 4. PFS 5. OS

156 patients from eight hospitals with stage IVb NPC, who failed first − line platinum-base chemotherapy and second-line single agent or combined chemotherapy treated with camrelizumab 536 patients with recurrent/metastatic NPC from seven trialsSix different treatment regimens - Pembrolizumab - Nivolumab - JS001 - Camrelizumab - Chemotherapy - Camrelizumab + chemotherapy

2021 2

Phase II

multicenter, open-label, single-arm

Lvet al. 1712

2019 2

Pooled analysis of trials

1. Grade 1–5 AEs and

1. Nivolumab (54.2%) and pembrolizumab (74.1%) exhibited the optimal safety regarding grade 1–5 AEs, whereas camrelizumab (16.1%) and nivolumab (17.4%) had the lowest grade 3–5 AEs 2. Treatment discontinuation due to AEs was most commonly recorded in pembrolizumab (18.5%), followed by camrelizumab + chemotherapy (13.0%) and JS001 (9.8%) and lowest in camrelizumab (2.2%) 3. As first-line therapy, camrelizumab + chemotherapy achieved higher ORR than with chemotherapy alone; when nivolumab was used as first-line therapy (in treatment-naïve patients), its ORR increased to 40.0% 4. As second- or later-line therapy, ORR was higher with camrelizumab (34.1%) followed by pembrolizumab (26.3%), JS001 (23.3%), and nivolumab (19.0%) 5. Pooled ORR was 28.4% for PD-L1-positive and 17.4% for PD-L1-negative patients 1. ORR was 20.5% (CR n = 1, PR n = 8), median DoR was 9.3 months, DCR was 54.5% 2. Median OS was 17.1 months and median PFS was 2.8 months 3. 1-year OS was 59% and PFS was 19.3% 4. No statistical correlation between ORR and biomarkers (Continues)

grade 3–5 AEs

2. ORR

Maet al. 1708

1. ORR 2. DoR, OS, PFS

44 patients with pretreated

2018 2

Multicenter phase II study

recurrent/metastatic NPC treated with nivolumab until PD

Two phase III studies on efficacy of different platinum based regimens done a few years later showed that GP had a significantly higher objective response rate (ORR), PFS, and OS compared with 5-FU 1702 or docetaxel 1703 plus platinum-based regimen.

There is no universal recommendation on the role of locoregional RT of the nasopharynx and neck in metastatic NPC patients. A multicenter phase III study on addi tion of locoregional RT to chemotherapy in patients with de novo metastatic NPC showed that chemotherapy plus